BackLakefront Biotherapeutics Overview
Lakefront Biotherapeutics

Lakefront Biotherapeutics P/E Ratio

Lakefront Biotherapeutics (GLPGF) has a P/E ratio of 4.08, below the Healthcare sector average of 21.65.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

4.08

P/E Ratio

4.08

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Lakefront Biotherapeutics (GLPGF) FAQ

The latest P/E ratio for GLPGF is 4.08. That is below the Healthcare sector average of 21.65. Investors often review this figure alongside Lakefront Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, GLPGF currently prints 4.08 for P/E ratio, while the sector average sits near 21.65. That is roughly 81.2% below the sector mean. Large gaps often invite a closer look at Lakefront Biotherapeutics's growth, margins, and balance sheet.

A P/E ratio of 4.08 for Lakefront Biotherapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (21.65) and with GLPGF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting GLPGF's P/E ratio (4.08), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lakefront Biotherapeutics's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.